Lenvatinib plus pucotenlimab

DRUG2 trials

Sponsors

Tongji Hospital

Conditions

Cholangiocarcinoma Non-resectable

Phase 2

Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

RecruitingNCT06192784

Tongji HospitalCholangiocarcinoma Non-resectable

Start: 2023-12-09End: 2025-06-30Target: 36Updated: 2024-01-09

Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

RecruitingNCT06192797

Tongji HospitalCholangiocarcinoma Non-resectable

Start: 2024-06-11End: 2028-06-30Target: 36Updated: 2024-11-05